Limited coverage criteria – deferiprone

Last updated on February 28, 2025

Return to Special Authority drug list 

Generic name

deferiprone

Strength & form

100 mg/mL, 1000 mg oral solution, tablet

Special Authority criteria

Approval period

Treatment of transfusion-dependent iron overload due to thalassemia syndromes, where iron chelation therapy is required, according to established criteria*, and when a Special Authority request is submitted by a hematologist.

Initial request: 1 year

Renewal request: 1 year

Practitioner exemptions

  • None

Special notes

  • None

Special Authority request form(s)

* Click on the Special Authority Form below for full criteria: